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Abstract
Objectives: We assessed the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and
acceptability to vaccinate in sub-Saharan African (SSA) countries. We further identified countries that fulfill the two GAVI
Alliance eligibility criteria to support nationwide HPV vaccination.
Methods: We conducted a systematic review of peer-reviewed studies on the knowledge and awareness of cervical cancer,
HPV and HPV vaccine, and willingness and acceptability to vaccinate. Trends in Diphtheria-tetanus-pertussis (DTP3) vaccine
coverage in SSA countries from 1990–2011 were extracted from the World Health Organization database.
Findings: The review revealed high levels of willingness and acceptability of HPV vaccine but low levels of knowledge and
awareness of cervical cancer, HPV or HPV vaccine. We identified only six countries to have met the two GAVI Alliance
requirements for supporting introduction of HPV vaccine: 1) the ability to deliver multi-dose vaccines for no less than 50% of
the target vaccination cohort in an average size district, and 2) achieving over 70% coverage of DTP3 vaccine nationally.
From 2008 through 2011 all SSA countries, with the exception of Mauritania and Nigeria, have reached or maintained DTP3
coverage at 70% or above.
Conclusion: There is an urgent need for more education to inform the public about HPV, HPV vaccine, and cervical cancer,
particularly to key demographics, (adolescents, parents and healthcare professionals), to leverage high levels of willingness
and acceptability of HPV vaccine towards successful implementation of HPV vaccination programs. There is unpreparedness
in most SSA countries to roll out national HPV vaccination as per the GAVI Alliance eligibility criteria for supporting
introduction of the vaccine. In countries that have met 70% DTP3 coverage, pilot programs need to be rolled out to identify
the best practice and strategies for delivering HPV vaccines to adolescents and also to qualify for GAVI Alliance support.
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Introduction
The introduction of vaccines has been one of the most effective
public health interventions for combating infectious diseases [1,2].
The establishment of the Expanded Programme on Immunization
(EPI) in 1974 by the World Health Organization (WHO) led to the
global eradication of smallpox and has greatly reduced the burden
of several infectious diseases, including poliomyelitis, measles,
tuberculosis, tetanus and diphtheria in many parts of the world
[2]. Despite slow progress in increasing vaccine access and
immunization coverage, the EPI has reported 83% coverage of
infants worldwide of the three doses of Diphtheria-tetanus-
pertussis (DTP3) vaccine in 2011, similar to coverage in 2009
(82%) and 2010 (85%) [1,3]. Expansion and delivery of life-saving
vaccines in the 2010–2020 ‘‘decade of vaccines’’ is expected to
save 6.4 million lives, valued at hundreds of billions of dollars in
low and middle-income countries [4]. Currently, DTP3 coverage
by age 12 months is a key indicator of immunization program
performance of a country and is associated with the level of
capacity to effectively manage and deliver a new vaccine to a
target cohort [5,6].
Worldwide, 15% of all cancer cases and nearly 26% of cancer
cases in developing countries are attributable to infectious agents,
particularly viruses [7]. Cervical cancer, which is caused by the
human papillomavirus (HPV), is the leading cause of cancer
mortality among women in sub-Saharan Africa (SSA) [8,9]. The
approval and recommendation of two vaccines – Gardasil and
Cervarix – provide a huge opportunity to curb the burden of
cervical cancer [10]. As one of the key strategies in preventing
cervical cancer in developed countries, providing HPV vaccines in
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low and middle income countries is a critical pillar for meeting the
global action plan for closing the cancer divide [5]. However,
outstanding barriers to achieving this goal in low-income countries
remain. These include high cost of vaccine and vaccine delivery
[11], low cervical cancer screening levels [12], poor health system
capabilities [11,13], inaccessibility to medical care [14], low
awareness and knowledge of HPV and cervical cancer[14–18],
and failure of cervical cancer to be recognized as a major health
concern [19].
Several recent developments have emphasized HPV vaccine as
an important prevention strategy. The 2009 WHO position paper
on HPV vaccines recommended they be included in routine
national immunization programs as a public health priority [20].
Furthermore, one of the goals of the 2006 Global Immunization
Vision and Strategy (GIVS) is to introduce new vaccines to all
eligible populations within five years of introduction in national
programs [3]. Additionally, major milestones during 2007–2011
have brought access to HPV vaccines within reach for many
adolescents in low-income countries. In May 2013, for the first
time ever, a public offer was made by GAVI Alliance for a price of
$4.50 per dose for both Gardasil and Cervarix to low-income
countries [21], a drastic reduction from $360 for the required three
doses [22,23].
Currently, the GAVI Alliance uses two criteria to determine
eligibility for vaccination support, including HPV vaccine: 1) a
DTP3 threshold of 70% national coverage (WHO/UNICEF
estimates) and 2) a pilot demonstration of the ability to deliver a
complete multi-dose series of vaccines to at least 50% of the target
vaccination cohort in an average sized district in a country [24].
Recently, Rwanda was the first country to take advantage of the
low pricing through a partnership with pharmaceutical manufac-
turer Merck, achieving 93% coverage of HPV vaccination of all
grade six adolescent girls in 2011 [25–27], which is, to the best of
our knowledge, the highest in the world. Through other sources of
subsidized HPV vaccines, 88.9% of girls were fully vaccinated in
Uganda using a school-based pilot program supported by PATH
International in 2009 [28]. A similar HPV vaccination pilot
initiative was recently undertaken in Cameroon [15], Tanzania
[29], Lesotho [30] and South Africa [31]. More recently, Kenya
became the first SSA country to receive GAVI Alliance support to
roll out a HPV vaccine pilot project (see: http://www.gavialliance.
org/support/nvs/human-papillomavirus-vaccine-support). GAVI
Alliance also announced that in 2014 it will support the first
nationwide introduction of HPV vaccine in Rwanda for girls of all
eligible ages, as well as other HPV demonstration projects in
Mozambique, Zimbabwe, Ghana, Madagascar, Malawi, Niger,
Sierra Leone, and Tanzania (see: http://www.gavialliance.org/
support/nvs/human-papillomavirus-vaccine-support).
These developments, coupled with SSA’s recent success in
reaching 70% coverage for other routine vaccines, namely
measles, hepatitis B, Influenza, tuberculosis and polio since 1990
[3], provide strong evidence of how introducing HPV vaccine can
be achieved in other countries meeting the GAVI Alliance
eligibility criteria. The success of pilot demonstrations in Rwanda,
South Africa, Cameroon, Lesotho, Tanzania and Uganda also
provide lessons on how to design and implement national HPV
vaccination programs tailored for a specific group of individuals in
resource-limited regions.
Nevertheless, introducing HPV vaccine in SSA offers unique
challenges, especially due to limited awareness of cervical cancer,
its relationship to HPV, concerns about safety and future fertility,
and political factors [32], as seen in recent cases in Rwanda
[26,27] and Cameroon [33]. These unsubstantiated rumors about
side effects or adverse outcomes that may not be casually related to
the vaccine may negatively impact public trust and adversely
impact HPV immunization programming leading to suspension of
the program altogether as recently experienced in Japan [34] and
India [35].
In this study, we assessed the knowledge and awareness of
cervical cancer, HPV and HPV vaccine, willingness and
acceptability to vaccinate through a systematic review of peer-
reviewed literature. We further identified the fulfillment of GAVI
Alliance eligibility criteria among countries in SSA. To the best of
our knowledge this is the first systematic review of the potential
readiness for introduction of HPV vaccine in the sub-continent,
which reveals further insight into some of the unique challenges
that need to be addressed.
Methods
Identification of Studies
Studies examining awareness, knowledge of cervical cancer,
HPV and acceptability of HPV vaccines in SSA were identified by
searching PubMed/MEDLINE (NCBI), Embase (Elsevier), Afri-
can Index Medicus (AIM), and POPLINE (K4Health) from their
earliest dates through July 11, 2013. Bibliographies of relevant
reviews and eligible studies were examined for additional sources.
The search was performed by a librarian (PAB) using terms for
papillomavirus vaccines and vaccination, acceptability or aware-
ness, and the names of all SSA countries (Appendix S1). The
search was conducted without language restriction. Titles and
abstracts of identified articles were reviewed by two authors (SP
and JGO) and categorized as relevant using the criteria outlined
below.
The review was conducted using methodology reported in the
National Health Service Centre for Reviews and Dissemination
report, supplemented by Harden’s recommendations for system-
atic reviews of qualitative studies [36]. We also adhered to
guidance on methods for conducting and reporting systematic
reviews in the PRISMA statement where it could be applied to
mixed method reviews [37]. Two authors (JGO and RGW)
appraised the quality of the studies using a checklist developed by
the National Institute for Health and Clinical Excellence [38], and
surveys using a checklist adapted from Pettigrew and Roberts [39]
provided in supplementary Table 1 and Table 2, respectively.
Inclusion Criteria
Studies included in the review needed to meet the following
criteria: 1) it occurred in a SSA country; 2) it was published in
2006 or later, after HPV vaccination was introduced; 3) it focused
on one or more of the three key demographics (adolescents,
parents/guardians, healthcare workers); and 4) it examined at least
one or more of the following key themes: a) level of awareness of
HPV and/or cervical cancer; b) level of knowledge of cervical
cancer and/or awareness; c) willingness to vaccinate; d) and
acceptability of HPV vaccine. Studies that conducted a pilot HPV
vaccination program were automatically included in the review.
Animal studies were excluded from the review.
Article Review
A systematic review of the identified studies was then performed
summarizing key results. The authors’ findings were treated as
primary data and studies were synthesized using a framework
approach. Data were extracted and organized by key information
such as demographic, method and sample size, and key findings of
the study about levels of knowledge, awareness, willingness and
acceptability. Any strategies for vaccination or increasing aware-
ness (whether recommended or implemented strategies) were also
HPV Vaccine and Acceptability to Vaccinate in SSA
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e90912
Table 1. A summary of countries included in the systematic review.
Total Number of Articles 29
Total Number of Studies 27
Total Number of Countries 13
Botswana 1
Cameroon 5
Ghana 1
Kenya 2
Lesotho 1
Mali 1
Nigeria 5
Rwanda 1
South Africa 4
Tanzania 4
Uganda 3
Zambia 1
Zimbabwe 1
Demographics of Studies* *Note: one study looked at multiple demographics Girls (Pupils)– 6
Medical Professionals – 8
HCW – 3
Gyn – 1
Nurses – 3
Non-traditional healers – 1
Parents – 5
Women – 10
University students – 1
Age 12–26 – 1
Age 12–84 – 1
Age 15–49 – 1
Age 16–64 – 1
Age 18–44 – 2
Age 18–65 – 2
Women from HIV-1 discordant couples – 1
Not Applicable/Unspecific – 2
Methods Survey – 17
Focus Groups – 2
School-based Vaccination – 2
Assessment of Vaccination Programs – 1
Case Control Study – 1
Cross-Sectional Study of Delivery Strategies - 1
Discussion/Interviews – 1
KAP Studies – 1
Randomized Controlled Trials – 1
Review – 1
Acceptability of HPV Vaccine (12 Studies) *Note – 1 study assessed two different vaccine
delivery strategies, resulting in two different levels of acceptability; *1 study looked at the
results of vaccination strategies in two different countries, resulting in two different levels
of acceptability. [14,15,25,28,30,31,41,42,53–55]
High – 12
Moderate - 2
Low – 0
Acceptability of cervical cancer Screening (1 study) [56] High – 1
Low – 0
Willingness to Recommend HPV Vaccines (5 Studies) [15,17,43,57,58] High – 5
HPV Vaccine and Acceptability to Vaccinate in SSA
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extracted along with factors influencing acceptability of HPV
vaccine.
Analysis
Levels of awareness, knowledge, acceptability and willingness
were broken down into these categories: 1) awareness of cervical
cancer, HPV and/or HPV vaccine; 2) knowledge of cervical
cancer, HPV and/or HPV vaccine; 3) acceptability of HPV
vaccine (and in one case, acceptability of cervical cancer
screening); and 4) willingness to vaccinate or get vaccinated.
Willingness was broken down further into categories based on how
each individual article defined it as seen in Table 1. Levels of
awareness, knowledge, acceptability and willingness to vaccinate
were summarized based on how each individual study categorized
the levels (high, low or moderate). The articles were then tallied for
each relevant category. Some articles had multiple levels of
awareness and knowledge, resulting in one article being counted
more than once (i.e. one article may have high awareness of
cervical cancer but low awareness of HPV). Strategies for
vaccination/increasing awareness and factors influencing accept-
ability provided qualitative insight and allowed us to identify
important themes for awareness, implementation and acceptability
of HPV vaccination.
Results
Overview of Studies Examined
The literature search returned 142 unique records as summa-
rized in the flow chart (Fig. S1). Review of selected article
bibliographies uncovered 10 other articles. A total of 124 relevant
articles were selected and reviewed and 29 articles based on 27
studies in 13 different SSA countries met the inclusion criteria.
Ten studies focused on women, with ages ranging from 12 to 84,
eight studies focused on medical professionals, five focused on
parents and six focused on girls in primary schools. Six countries
implemented HPV vaccination pilot programs (Cameroon,
Lesotho, Rwanda, South Africa, Tanzania and Uganda). Table 1
shows a detailed summary of identified studies and Table 2
summarizes the key findings from each study.
Study Quality
Two qualitative studies were considered to be of good standard
while one was considered moderate and one was considered poor.
Nearly all of the surveys were well conducted and 17 of these had a
sample size greater than 200 respondents. Sixteen of those had a
response rate greater than 70%. The remaining studies varied in
quality from moderately good to poor [30].
Awareness and Knowledge of Cervical Cancer and HPV
Fifteen studies examined awareness of cervical cancer, HPV
and/or HPV vaccine among specific demographic groups. Levels
of awareness were mixed with 11 studies demonstrating high
awareness, nine studies demonstrating low awareness and two
studies demonstrating moderate awareness. Levels of knowledge of
cervical cancer and HPV were consistently low. Of the 16 studies
examining knowledge of cervical cancer, HPV and HPV vaccine,
all noted low levels of knowledge, three reported no knowledge,
and two reported moderate knowledge. Only one study specified a
moderately high level of knowledge of HPV vaccine.
Willingness and Acceptability of HPV Vaccine and
Cervical Cancer Screening
Categories of willingness varied across studies: willingness to
recommend HPV vaccine (five studies); willingness to get
vaccinated (four); willingness to get daughter vaccinated (four);
willingness to participate in vaccine trials (one); ‘‘interest’’ in the
vaccine for daughters (one); and ‘‘interest in learning more about
the vaccine’’ (one). All studies reported high rates of willingness in
their respective categories. Twelve studies examined acceptability
levels of HPV vaccine and one study examined acceptability of
Table 1. Cont.
Low – 0
Willingness to Get Vaccinated (4 Studies) [42,43,53,59] High – 4
Low – 0
Willingness to Get Daughter Vaccinated (4 Studies) [14,17,40,53] High – 4
Low – 0
Willingness to Participate in Trials (1 Study) [60] High – 1
Low – 0
Interest in Vaccine for Daughters (1 Study) [61] High – 1
Low – 0
Interest in Learning More about Vaccine (1 Study) [62] High – 1
Low – 0
Knowledge of Cervical Cancer, HPV and/or HPV Vaccine (16 Studies) [14,29,42,56–67] High – 0
Moderately High - 1
Moderate - 2
Low – 16
None – 3
Awareness of CC, HPV and/or HPV Vaccine (15 Studies) [14,15,17,40–43,53,55–57,59,61,64,67] High – 11
Low – 9
Moderate – 2
doi:10.1371/journal.pone.0090912.t001
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cervical cancer screening (Table 1). All 12 studies reported high
levels of acceptability of HPV vaccine. However, multiple levels of
acceptability were found within the studies because some assessed
and compared different vaccine delivery strategies within and in
different countries.
Strategies and Factors for Increasing Awareness and
Acceptability of HPV Vaccine
Of the 27 studies, 26 discussed strategies for vaccination and
increasing awareness. Studies in the six countries in the review
where HPV vaccination pilot programs were conducted discussed
the implementation strategies used for vaccination while the
remaining countries in this review discussed recommended
strategies for implementation. Rwanda, South Africa Tanzania
and Uganda used school-based strategies achieving 93.2%, 97.8%,
71.6% and 88.9% vaccine uptake, respectively [25,28]. Lesotho
used a mixed vaccination strategy (clinic and school-based) [30].
Cameroon used three distinct approaches to deliver vaccines
namely school-based, health facilities and community outreach
programs in churches and mother-to-daughter [15,17,18]. In
addition, all studies, with the exception of Lesotho specifically
mentioned that sensitization campaigns were used in their
vaccination strategies [30]. Rwanda conducted a nationwide
campaign while South Africa, Tanzania, Cameroon and Uganda
conducted focused educational campaigns to targeted groups
[15,25,28,29,31]. Two studies in both Botswana [40] and Ghana
[41] recommended schools as the ideal venue for HPV vaccine
delivery.
Education for increasing awareness was a strong theme
throughout the majority of studies. Recommended strategies to
implement sensitization programs included community health
education programs, continuing medical education for nurses,
midwives, doctors and other healthcare workers, and health
promotion and policy programs including awareness through
social and mass media (i.e. public radio, television and folk media).
Factors influencing acceptability also varied. Twelve studies
addressed reasons for acceptability of HPV vaccine. Two studies in
Nigeria [42,43] discussed reasons for rejection among nurses and
university students while one study in Tanzania [29] noted that
head teachers at three private schools would not permit
vaccination, fearing negative parental feedback. In Nigeria [43],
nurses’ reasons included: insufficient knowledge about HPV
vaccine; girls were too young and not sexually active; girls are
not yet at risk to HPV infections; and it encourages promiscuity. In
addition, university students who rejected the HPV vaccine based
their decisions on fear of side effects, fear of the unknown, and
controversies surrounding the vaccine [42]. Themes surrounding
acceptability included access to the vaccine, side effects and
effectiveness, protection against and prevention of cervical cancer,
provider and teacher recommendations, support from the
National Immunization Program and cost [42,43].
GAVI Alliance Eligibility Based on DTP3 Levels and Pilot
Demonstration Projects on HPV Vaccine Delivery
Of the 13 countries included in this review, 12 have achieved
70% coverage or higher of the DTP3 vaccine since 2003, one of
GAVI Alliance’s criteria for vaccine support; the exception is
Nigeria (Table 3). Six of those countries had an HPV vaccination
pilot program (Cameroon, Lesotho, Rwanda, South Africa,
Tanzania and Uganda). There were 31 sub-Saharan African
countries not included in the review because there were no studies
based in these countries that met the inclusion criteria. The
majority of these countries did not start consistently reaching
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coverage levels of 70% or higher until 2005 (Table 4). From 2008
through 2011, all countries, with the exception of Mauritania,
have maintained coverage at 70% or above (Table 4).
Discussion
This review identified low levels of knowledge and mixed levels
of awareness on cervical cancer, HPV and HPV vaccine, and high
levels of acceptability of HPV vaccine among all key demograph-
ics. In particular, high acceptability of HPV vaccine despite the
lack of knowledge about cervical cancer and HPV represents an
opportunity for increased education and awareness strategies
about cervical cancer, HPV and HPV vaccine. This is important
to help key demographics understand the transmission of HPV, its
characteristics and associated risks [17,44], and the benefits of
HPV vaccine.
Engaging all key demographics through improved and in-
creased education will elevate public trust, which is a critical
component of successful implementation of widespread vaccine
coverage. Incidences such as those seen in Japan, India and
Rwanda [26,27,34,35,45] have challenged public trust in HPV
vaccines. Additionally, the qualitative insight provided by this
review shows that factors influencing acceptability are often tied to
issues of public trust, such as concerns over side effects and safety.
This is not only a concern in low- and mid-income countries. For
instance, Japan’s Ministry of Health recently withdrew its
recommendation for administering HPV vaccine because of
reports of side effects, although it still pays for the vaccine for
parents consenting to immunize their daughters [34].
Anti-vaccination groups frequently post inaccurate information
about vaccine side effects on the web, which is publicized by both
local and national media [46,47]. These examples indicate the
need to constantly engage and educate the public to avoid the risk
of health programs failing [48,49]. While it may not be advisable
or possible to respond to all such misinformation, it is essential to
counteract it by providing scientifically correct information in a
proactive manner so people will seek appropriate medical advice
for clarification [50].
Tailored community-based interventions and sensitization
programs are a viable means to achieve this for multiple reasons.
They have the potential to curb concerns about safety and
effectiveness of the vaccine while dispelling negative myths or
controversies [45]. Specific training for healthcare workers, the
first contact point for patients, will provide them with the accurate
knowledge and information necessary to discuss cervical cancer,
HPV and HPV vaccine with their patients as well as the ability to
properly detect, screen and test for HPV and cervical cancer
[18,43].
In addition to understanding levels of knowledge, awareness and
acceptability, this review uncovered encouraging trends concern-
ing SSA countries’ eligibility for GAVI Alliance support. Only six
countries have currently met the two criteria required by the
GAVI Alliance to support introduction of the HPV vaccine at a
lower cost of US$4.50 per dose [21]. Of the six, Rwanda has
already achieved 93.2% vaccine coverage among girls in grade six
and is taking the lead to enroll all eligible girls for HPV
vaccination through GAVI alliance support in 2014.
Further, our analysis of national vaccine coverage for DTP3 in
SSA shows rapid expansion from just one country reaching 80%
in 1980 to 35 countries in 2010 [6]. Of the 31 countries that did
not meet the review inclusion criteria, only Mauritania did not
consistently achieve GAVI Alliance’s eligibility criteria requiring
DTP3 coverage levels greater than or equal to 70% (Table 4). Of
the countries included in this review, only Nigeria failed to meet
this threshold. The challenges in Nigeria are perhaps unique
especially in the context of the recent polio vaccine boycott and
killings [51]. This calls for interrogating vaccine acceptance
determinants using, for instance, the health-belief model [45] and
addressing these through a re-emphasis on contextualized public
communication and education to mitigate resistance and to build
trust [6].
Such consistently high DTP3 coverage levels among the
majority of SSA countries indicates structural health system
capabilities to deliver simple vaccines to the population [1,3]. This
further demonstrates the feasibility for these countries to deliver
multi-dose vaccines, such as HPV, for 50% of a target vaccination
cohort in an average size district, which would qualify them for
GAVI Alliance support. Support from GAVI Alliance is a critical
and essential gateway to preventing cervical cancer through
vaccination in SSA and bridging the global cancer divide [5].
Table 3. Reported Estimates of DTP3 Coverage in sub-Saharan Countries included in this review.
Country 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990
Botswana 99 95 97 94 98 99 99 89 93 87 74 85 85 82 76 83 80 78 57 59 53 56
*Cameroon 82 84 80 84 82 81 80 73 73 63 43 53 48 48 43 44 46 38 34 37 34 36
Ghana 91 94 94 93 94 84 84 80 80 99 76 84 72 68 60 51 51 48 48 40 40 50
Kenya 88 83 75 85 81 80 76 73 73 84 80 63 79 64 36 77 84 50 42 40 41 42
*Lesotho 69 75 72 91 91 90 87 71 62 60 72 69 58 64 56 53 52 55 47 66 67 71
Mali 88 92 89 99 91 95 95 86 79 74 61 54 47 56 52 53 49 39 46 38 34 42
Nigeria 61 74 71 57 69 72 38 38 38 21 21 26 34 44 29 43 39 56
*Rwanda 97 97 97 97 97 99 95 89 96 88 77 90 85 77 98 90 83 85 89 57
*South Africa 97 91 99 98 97 99 97 89 94 82 81 96 76 76 73 73 72 81 79 81 74
*Tanzania 92 91 85 86 83 90 90 95 95 89 87 79 76 79 79 82 81 84 83 83 81 78
*Uganda 82 80 83 79 85 80 84 87 81 72 61 58 60 56 61 72 74 79 73 71 77 77
Zambia 81 84 98 95 92 97 91 94 91 88 76 92 70 83 82 86 67 61 91 71
Zimbabwe 93 89 73 75 85 90 90 85 80 75 75 77 81 70 78 80 83 80 73 79 89 78
Source: WHO http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragedtp3.html.
*Country with HPV Vaccination Pilot Program.
doi:10.1371/journal.pone.0090912.t003
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As this review shows, engaging all stakeholders at multiple levels
in countries that meet these requirements is necessary for
successful HPV vaccine implementation. Governments should
leverage the high levels of acceptability and willingness to
vaccinate by increasing education for healthcare workers, wom-
en/girls and parents/guardians. Governments should also deter-
mine appropriate strategies for disseminating information and
vaccine delivery by building upon current infrastructures, such as
existing EPIs and school-based programs. This has been shown to
be an effective approach because it relies on the involvement of
multiple critical stakeholders from the government down to the
community level, as seen in Rwanda, South Africa, Uganda and
Tanzania [2,6,25,26,28,31]. Tailored community-based sensitiza-
tion campaigns aimed at a targeted population, as used in
Cameroon, also proved effective [15,17,18]. Thus, using hybrid
delivery system models may be more beneficial as per country
experiences in the EPI and can help inform and determine best
practices when developing HPV vaccine pilot programs [4,6].
Conclusions
The objective of this study was to provide a systematic review of
knowledge and awareness of HPV vaccine, willingness to
vaccinate, and acceptability of the vaccine, as well as fulfillment
of GAVI Alliance’s eligibility criteria for vaccine assistance in SSA.
To the best of our knowledge, this is the first systematic review of
the potential readiness for introduction of HPV vaccine in the sub-
continent. Examining the region collectively offers insight into its
readiness and ability to implement HPV vaccination on a broader
scale while shedding light on the successes, challenges, and lessons
of implementation.
From this review, three important themes have emerged. (1)
There are high levels of acceptability and willingness to vaccinate.
Table 4. Reported Estimates of DTP3 Coverage in Countries Not Included in the Review.
Country Name 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990
Angola 86 91 73 81 83 44 47 59 46 47 41 31 22 45 41 28 42 27 30 21 26 24
Benin 99 98 98 93 97 93 93 83 88 93 84 88 90 81 78 80 89 86 77 79 68 78
Burkina Faso 91 91 99 99 99 95 96 88 84 69 68 57 34 40 70 48 47 41 47 39
Burundi 99 96 99 92 99 92 87 83 94 95 59 68 63 50 60 55 63 48 63 80 83 86
Cape Verde 90 99 74 82 81 72 73 75 87 94 78 86 69 80 78 73 73 99 99 99 88
Central African
Republic (the)
64 58 76 51 84 88 46 50 28 23 23 29 27 45 53 53 45 40 31 66 61
Chad 70 83 75 43 70 77 58 50 47 40 27 28 33 23 24 20 18 18 13 10 18 20
Comoros (the) 83 74 83 81 75 69 68 76 80 89 70 70 75 48 60 75 58 70 38 52 94
Congo (the) 90 90 91 89 80 79 65 67 50 41 31 33 29 23 75 47 60 65 70 77
Coˆte d’Ivoire 62 85 81 74 76 77 56 50 48 73 59 62 58 64 70 55 41 41 50 49 54
Democratic
Republic of the
Congo (the)
90 78 92 83 87 77 73 64 49 43 32 40 25 18 18 18 23 29 29 16 36
Equatorial Guinea 54 44 74 74 41 34 34 46 41 65 32 32 40 81 64 64 60 64
Eritrea 94 85 85 85 80 80 80 80 75 70 65 52 56 60 60 46 35 36 28
Ethiopia 87 86 79 81 73 72 69 66 52 51 51 42 40 37 41 42 57 37 28 13 21 49
Gabon 75 67 76 82 81 44 40 40 40 33 28 10 31 37 54 61 70 59 65 66 72 78
Gambia (the) 96 95 94 96 94 93 89 92 90 80 96 74 88 97 96 96 96 93 90 85 85 92
Guinea 85 90 85 70 93 89 86 69 69 58 57 57 57 56 53 48 73 73 52 41 20
Guinea-Bissau 89 86 82 79 96 77 80 80 77 50 47 6 63 53 45 74 65 67 63 61
Liberia 77 75 92 92 88 88 87 31 38 51 62 48 23 19 26 45 45
Madagascar 89 85 89 88 95 93 92 75 87 62 37 80 71 54 61 73 74 66 66 65 53 71
Malawi 97 93 93 91 87 99 93 89 84 64 90 75 85 96 95 90 97 98 91 86 81 80
Mauritania 75 64 64 74 75 68 71 70 76 83 61 31 26 28 50 50 50 44 39 29 33
Mauritius 98 99 99 99 97 97 97 98 92 93 88 85 89 90 89 93 89 88 85
Mozambique 76 74 76 80 75 98 75 65 85 84 80 88 81 77 61 60 57 55 49 50 46 46
Namibia 82 83 83 83 86 74 86 81 92 77 63 79 72 74 66 70 74 79 73 70 87 59
Sao Tome and
Principe
96 98 98 99 97 99 97 99 94 91 92 82 73 73 68 79 60 68 87 92
Senegal 83 70 86 88 94 89 84 87 73 60 52 52 60 59 59 70 80 57 52 46 51 66
Seychelles 99 99 99 99 99 99 99 99 99 99 96 99 99 98 99 98 96 96 99
Sierra Leone 76 76 91 87 79 95 64 61 70 52 38 24 56 26 65 43 41 63 64 56 83
Swaziland 91 89 72 80 68 68 71 83 95 77 77 98 99 84 82 82 82 96 89 93 79 89
Togo 92 92 89 89 88 87 82 71 72 59 43 50 48 36 40 27 47 71 75 76 82 77
Source: WHO http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tscoveragedtp3.htm.
doi:10.1371/journal.pone.0090912.t004
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These should be harnessed by national governments to establish
and implement HPV vaccination strategies that build upon
existing infrastructures. (2) Overall, six SSA countries qualify for
GAVI Alliance assistance to introduce HPV vaccine at a national
level. (3) Lastly, there is a need for increased education and
awareness among all three key demographics about HPV, HPV
vaccine and the burden of cervical cancer as a disease.
The combination of required DTP3 coverage, high acceptabil-
ity of HPV vaccine and high willingness to vaccinate, indicates the
readiness and potential for SSA countries to introduce HPV
vaccine to the population. Successfully doing so will depend on
implementing tailored delivery strategies that fit each country’s
needs and engaging the government at all levels. Building upon the
lessons learned from GAVI Alliance eligible SSA countries will
pave the way for those SSA countries still working to meet the
criteria. These countries should also take advantage of and benefit
from the ‘‘decade of vaccines’’ and the GIVS when there is a re-
dedication by donors to meet these goals [4,6].
Limitations
There were some limitations in this review. The studies
reviewed lacked consistency in regards to psychometric charac-
teristics used. Not all of the studies used a theoretical framework,
consistent labeling of themes examined, or rigorous testing and
validation of the measures as previously outlined [52]. While some
assessed levels of knowledge and awareness of cervical cancer and
HPV, others did not. Still others discussed levels of willingness to
vaccinate and acceptability of HPV vaccine while others did not.
Some studies discussed all themes. This indicates a need for more
standardized methods on awareness and knowledge of HPV and
HPV vaccine, and acceptability and willingness to vaccinate to
provide better insight to guide health care practitioners in
developing successful community and clinical interventions and
scaling up HPV vaccination. Every effort was made to include all
studies but it is possible some were missed.
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